News coverage about Ra Pharmaceuticals (NASDAQ:RARX) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ra Pharmaceuticals earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.8305495454226 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Ra Pharmaceuticals to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference (finance.yahoo.com)
- Ra Pharmaceuticals (RARX) vs. The Competition Financial Analysis (americanbankingnews.com)
- Ra Pharmaceuticals (RARX) Given “Buy” Rating at Royal Bank Of Canada (americanbankingnews.com)
- Ra Pharmaceuticals Inc (bloomberg.com)
- Why Ra Pharmaceuticals, Inc. Got Hammered Today (finance.yahoo.com)
Ra Pharmaceuticals (NASDAQ RARX) traded down $0.16 on Friday, reaching $7.51. 247,463 shares of the company’s stock were exchanged, compared to its average volume of 252,803. Ra Pharmaceuticals has a 1 year low of $7.15 and a 1 year high of $27.84.
Several analysts recently issued reports on the stock. Zacks Investment Research raised shares of Ra Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, September 19th. Credit Suisse Group lifted their price objective on shares of Ra Pharmaceuticals from $19.00 to $23.00 and gave the stock an “outperform” rating in a report on Friday, November 10th. Jefferies Group set a $25.00 price objective on shares of Ra Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 25th. BMO Capital Markets lifted their price objective on shares of Ra Pharmaceuticals in a report on Tuesday. Finally, Royal Bank Of Canada initiated coverage on shares of Ra Pharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating and a $21.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $23.20.
WARNING: This piece was posted by Week Herald and is the property of of Week Herald. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://weekherald.com/2017/12/09/ra-pharmaceuticals-rarx-given-coverage-optimism-score-of-0-17.html.
About Ra Pharmaceuticals
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Ratings for Ra Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.